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ABSTRACT 
 
Although aging is considered to be an unavoidable event, recent experimental evidence suggests that the 
process can be counteracted.  Intracellular calcium (Ca2+i) dyshomeostasis, mitochondrial dysfunction, oxidative 
stress, and lipid dysregulation are critical factors that contribute to senescence-related processes.  Ceramides, a 
pleiotropic class of sphingolipids, are important mediators of cellular senescence, but their role in neuronal 
aging is still largely unexplored.  In this study, we investigated the effects of L-cycloserine (L-CS), an inhibitor of 
the de novo ceramide biosynthesis, on the aging phenotype of cortical neurons cultured for 22 days, a setting 
employed as an in vitro model of senescence.  Our findings indicate that, compared to control cultures, ‘aged’ 
neurons display dysregulation of [Ca2+]i levels, mitochondrial dysfunction, increased generation of reactive 
oxygen species (ROS), altered synaptic activity as well as the activation of neuronal death-related molecules.  
Treatment with L-CS positively affected the senescent phenotype, a result associated with recovery of neuronal 
[Ca2+]i signaling and reduction of mitochondrial dysfunction and ROS generation.  The results suggest that the 
de novo ceramide biosynthesis represents a critical intermediate in the molecular and functional cascade 
leading to neuronal senescence and identify ceramide biosynthesis inhibitors as promising pharmacological 
tools to decrease age-related neuronal dysfunctions. 
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INTRODUCTION 
 
Aging is the time-dependent process characterized by the 
loss of the physiological integrity of living organisms [1].  
Although this process has been long considered to be 
unavoidable, recent evidence has shown that it can be 
delayed, if not altogether interrupted [2].  Many factors, 
including environmental exposure and molecular 
changes, contribute to the senescence-related processes 
[1,3].  The molecular effectors promote several cellular 
modifications like DNA damage, the activation of cell 
death pathways, the loss of proteostasis, cation 
dyshomeostasis, mitochondria dysfunction, and lipid 
dysregulation [1,4–6]. 
 
Ceramides are a class of sphingolipids involved in a 
wide array of biological functions including cell growth, 
proliferation, differentiation, and programmed cell 
death as well as cellular senescence [7]. The application 
to cell cultures of exogenous ceramides induces, in a 
dose-dependent and reversible manner, the expression 
of senescence markers [8]. In parallel, cellular 
senescence is associated with the increase of ceramide 
levels, a phenomenon found in age-related neurological 
conditions like Alzheimer’s disease (AD), Parkinson’s 
disease (PD), and Amyotrophic Lateral Sclerosis (ALS) 
patients as well as in brain aging [9–13]. 
 
Ceramides originate from one of two main enzyme-
mediated processes: de novo biosynthesis from 
palmitoyl-CoA and serine, or cleavage of sphingolipid 
precursors in membranes [14]. The former pathway 
involves three sequential reactions in which the enzyme 
serine palmitoyl transferase (SPT) serves as rate-
limiting step [14]. Importantly, pharmacological 
blockade of SPT activity has shown promising anti-
aging and neuroprotective effects in in vitro and in vivo 
models of cellular senescence [15,16].   
 
To gain further insights on the role played by ceramides 
in neuronal aging, we used L-cycloserine (L-CS), an 
amino acid that inhibits SPT activity both safely and 
selectively, and has been employed both in vitro and in 
vivo settings to reduce de novo ceramide biosynthesis 
[15,17–20]. We evaluated age-driven changes occurring 
in young and aging neuronal cultures exposed to vehicle 
or L-CS, focusing on alterations in cytosolic and 
subcellular calcium [Ca2+]i handling, mitochondrial 
functioning, spontaneous neuronal Ca2+ signaling, and 
activation of age-related and ceramide-driven molecular 
pathways. 
 
RESULTS 
 
To examine the effects of L-CS on neuronal aging, 
experiments were performed in long-term culture of 
primary cortical neurons (hereafter termed ‘aged’ 
neurons) used here as an in vitro model of neuronal 
senescence [21–23].  Cultures were maintained for 18-
19 days in vitro (DIV) and then treated with L-CS (30 
µM) or vehicle (serum-free medium) for an additional 
three days.  At the end of treatment (at 21-22 DIV), 
cultures were analyzed for morphological and 
functional changes or harvested for further biochemical 
analyses (Fig. 1A).  Data collected from aged neurons 
were compared with those obtained from vehicle- or 
drug-treated cultures at 11-12 DIV and assayed at 14-15 
DIV (hereafter termed ‘control’ neurons).  Routinely 
performed visual inspections of the cultures showed that 
aged neurons did not display overt signs of death or 
injury (Fig. 1B), thereby supporting the notion that the 
functional and biochemical changes that we have 
observed occurred upstream of mechanisms leading to 
neuronal death. 
 
L-CS reduces de novo ceramide biosynthesis in aged 
cultured neurons 
 
To test the drug-driven effects on ceramide 
biosynthesis, we quantified sphingolipids and ceramides 
by Liquid Chromatography/Mass Spectrometry 
(LC/MS-MS) in lipid extracts obtained from control and 
aged cultures that underwent vehicle- or L-CS-treatment 
(Fig. 1A, B).  Analysis of the lipid profiles indicates 
that aged neurons respond to the 3-day L-CS treatment 
with a significant reduction in the levels of total 
ceramides (d18:1/16:0, d18:1/18:0, d18:1/22:0, and 
d18:1/24:0; Fig. 1C) and sphinganine (Supplementary 
Fig. 1 and 2).  Aged cultures also show a modest 
increase in ceramide levels when compared to control 
neurons that do not reach statistical significance 
(Supplementary Fig. 1 and 2).  Surprisingly, Sptlc-2 
gene expression was decreased in vehicle-treated aged 
cultures (Supplementary Fig. 2D), an effect related to 
the potential divergence between Sptlc-2 transcript 
abundance and the protein levels observed in aging-
related conditions [24].  Of note, the ceramide reduction 
appears to be mainly driven by inhibition of the de novo 
pathway as sphinganine (an intermediate of the de novo 
pathway), but not sphingosine (which can generate 
ceramide through sphingomyelin hydrolysis), was found 
to be affected by the L-CS treatment (Supplementary 
Fig. 1 and 2). 
  
L-CS reduces resting Ca2+ levels in aged neurons 
 
The effects of 3-day L-CS or vehicle treatment on 
[Ca2+]i were measured by using the high-affinity 
(Kd≈140nM) ratiometric dye fura-2.  The analysis of 
resting fura-2 signals showed that no regional 
differences in [Ca2+]i levels were detectable in proximal 
or distal dendrites of aged or control neurons treated  
www.aging-us.com 6338 AGING 
  
 
 
Figure 1.  Effects of aging and L-CS on resting calcium (Ca2+) levels in cortical neurons.  (A) The pictogram illustrates the 
experimental paradigm employed in the study.  (B) Representative brightfield micrographs of control and aged neuronal cultures 
treated either with L-CS or vehicle (scale bar 100 µm).  Please, note that aged cultures are devoid of signs of neuronal death.  (C) Bar 
graphs depict the relative abundance of ceramides in vehicle- and L-CS-treated aged neurons (n=3 for both conditions).  (D) 
Representative fluorescent micrograph of a fura-2-loaded cultured cortical neuron (the image reports dye emission when excited at 
380 nm, scale bar 25 µm).  (E) Bar graphs depict dendritic Ca2+ levels of vehicle- or L-CS-treated control neurons (vehicle: n=102 
proximal and n=85 distal dendrites from 43 neurons; L-CS: n=115 proximal and n=84 distal dendrites from 38 neurons; p>0.05).  (F) 
Bar graphs depict dendritic Ca2+ levels of vehicle- or L-CS-treated aged neurons (vehicle: n=182 proximal and n=156 distal dendrites 
from 40 neurons; L-CS: n=177 proximal and n=155 distal dendrites from 44 neurons; p>0.05).  (G) Bar graphs depict somatic Ca2+ 
levels of vehicle- or L-CS-treated control and aged neurons (ControlVeh: n=1357 cells and ControlL-CS n=1015; AgedVeh n=539 cells and 
AgedL-CS n=497 cells obtained from 10-23 independent experiments).  In C and E-F means were compared by unpaired Student t-test.  
In G means were compared by two-way ANOVA followed by Tukey post-hoc test.  * indicates p<0.05, *** p<0.001. 
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Figure 2.  Effects of aging and L-CS on intracellular Ca2+ stores and NCX activity in cortical neurons.  (A) Time course of 
CCCP-stimulated Ca2+ release from mitochondria.  Traces represent the average response to a 3 min exposure to 5 µM CCCP 
(ControlVeh: n=226 cells and ControlL-CS n=140; AgedVeh n=91 cells and AgedL-CS n=67 cells obtained from 7-19 independent 
experiments).  (B) Dot plots depict Ca2+ peak obtained in the four study groups.  (C) Dot plots depict Ca2+ changes expressed as AUC 
(a.u.).  (D) Time course of CPA-stimulated Ca2+ release from the ER.  Traces represent the average response to a 2 min exposure to 10 
µM CPA (ControlVeh: n=50 cells and ControlL-CS n=33; AgedVeh n=54 cells and AgedL-CS n=48 cells obtained from 3-4 independent 
experiments).  (E) Dot plots depict Ca2+ peak obtained in the four study groups.  (F) Dot plots depict Ca2+ changes expressed as AUC 
(a.u.).  (G) Time course of NCX activity imaged by stimulating exchanger reverse operational mode (ControlVeh: n=163 cells and 
ControlL-CS n=122; AgedVeh n=106 cells and AgedL-CS n=98 cells obtained from 2 independent experiments).  (H) Dot plots depict Ca2+ 
peak obtained in the four study groups.  (I) Dot plots depict Ca2+ changes expressed as AUC (a.u.).  Means were compared by two-way 
ANOVA followed by Tukey post-hoc test.  * indicates p<0.05, *** p<0.001.  
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with either vehicle or L-CS (Fig. 1D-F).  By contrast, L-
CS treatment caused a reduction in resting somatic 
[Ca2+]i levels in aged neurons (Fig. 1G). Of note, a 
≈40% increase in resting [Ca2+]i was observed when 
comparing vehicle-treated control and aged neurons, 
thereby lending support to the notion that our in vitro 
senescence model exhibits signs of age-dependent Ca2+ 
dyshomeostasis [5,25].  No significant differences were 
observed when comparing vehicle- and drug-treated 
control neurons (Fig. 1G).  
 
L-CS treatment marginally affects main neuronal 
Ca2+ stores 
 
Mitochondria and the endoplasmic reticulum (ER) 
constitute the main intracellular Ca2+ stores.  To test 
whether Ca2+ accumulation in these organelles is 
affected by L-CS treatment, fura-2-loaded control and 
aged neurons were exposed to 5 µM carbonyl cyanide 
3-chlorophenylhydrazone (CCCP, a mitochondrial 
uncoupler that collapses the mitochondrial membrane 
potential, Δp) or 10 µM cyclopiazonic acid [CPA, a 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 
inhibitor], two agent employed to promote cation 
release from mitochondria or the ER, respectively.  
Analysis of the cytosolic [Ca2+]i changes showed that 
exposure to L-CS did not affect mitochondrial Ca2+ 
release (Fig. 2A-C).  A significant increase in 
mitochondrial Ca2+ release was instead found in aged 
neurons (Fig. 2A-C).  As our cultures showed modest 
and inconsistent CPA-dependent ER-Ca2+release (data 
not shown) and to facilitate the evaluation of this 
pathway, ER was pre-loaded with Ca2+ derived from the 
opening of the voltage-gated Ca2+ channels (VGCCs) as 
result of a 5-min depolarization induced by exposing 
cultures to 60 mM K+.   Compared to vehicle-treated 
and age-matched neurons, Ca2+ released from the ER 
was found to be lower in L-CS-treated control cultures 
(Fig. 2D-F).  No differences were observed when 
comparing vehicle-treated control neurons with vehicle- 
and L-CS-treated aged cultures (Fig. 2D-F). 
 
L-CS treatment does not modify NCX activity 
 
Ceramides can modulate the activity of the 
plasmalemmal Na+-Ca2+ exchanger (NCX) [26], a low 
capacitance high-affinity system that critically regulates 
cellular [Ca2+]i.  We, therefore, investigated the effects 
of ceramide on NCX functioning in L-CS or vehicle-
treated cultures.  Data obtained from this set of 
experiments were compared with the ones originated 
from age-matched and vehicle-treated sister cultures.  In 
the experiments, fura-2 loaded neurons were exposed to 
a Ca2+ free medium while in the presence of the Na+/K+-
ATPase pump blocker, ouabain (100 µM), a maneuver 
set to promote the intracellular accumulation of Na+.  
Ouabain-treated cultures were then switched to a Na+-
free medium to force the NCX to operate in the reverse 
mode to promote Ca2+ influx.  Analysis of the cytosolic 
[Ca2+]i rises showed that L-CS does not affect NCX 
activity in control and aged cultures treated with either 
vehicle- or L-CS (Fig. 2G-H). Changes in NCX 
functioning were observed; however, when comparing 
[Ca2+]i rises in control and aged cultures (Fig. 2G-H). 
 
L-CS treatment reduces age-driven mitochondrial 
dysfunction 
 
Mitochondrial functioning is a key target of the aging 
process [2,21].  In our experimental setting, effects on 
the organelle membrane potential were assessed by 
employing tetramethyl rhodamine ethyl ester (TMRE), 
a mitochondrial probe sensitive to changes of Δp. 
TMRE-loaded neurons were imaged for up to 60 
seconds under resting conditions and after exposure to 
10 µM CCCP, a maneuver that promotes a rapid and 
complete loss of Δp.  Data from this set of experiments 
indicate that aging neurons display signs of 
mitochondria dysfunction when compared to control 
cultures.  L-CS treatment was effective in reducing the 
Δp loss in aging neurons (Fig. 3A-C). A modest (≈10%) 
increase was also observed in L-CS-treated control 
neurons when compared with age-matched cultures 
(Fig. 3A-C).  In a subset of experiments, we also 
evaluated age-dependent changes in mitochondrial 
morphology of the cultured neurons. To that aim, 
neurons loaded with Mitotracker, a Δp -independent 
mitochondrial stain, were imaged with super-resolution 
confocal microscopy and analyzed with the 
Mitochondrial Network Analysis (MiNA) toolkit [27].  
Surprisingly, no significant age-dependent 
morphological changes were found (Fig. 3D and 
Supplementary Table 1). 
 
L-CS treatment reduces reactive oxygen species 
(ROS) generation in aged cultures 
 
Aberrant ROS generation and accumulation of ROS-
driven by-products are key features of aging [28].  To 
assess the effect of L-CS treatment on ROS production, 
we employed the probe hydroethidine (HEt).  Cortical 
cultures were loaded with HEt and basal fluorescence 
signals recorded.  The results show that aged neurons 
exhibit increased ROS production, compared to controls 
(Fig. 3E).  L-CS administration abrogated the effects of 
age (Fig. 3E). 
 
L-CS treatment reduces age-driven neuronal 
hyperexcitability in vitro 
 
To assess whether L-CS treatment affects spontaneous 
[Ca2+]i transients, an index of neurodegenerative 
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hyperexcitability, we eployed high-speed real-time 
microfluorimetric Ca2+ imaging [29].  Cultures were 
loaded with the single wavelength, high-affinity (Kd ≈ 
335 nM) and Ca2+ sensitive fluorescent probe fluo-4 and 
spontaneous changes in somatic [Ca2+]i were evaluated 
in terms of spike frequency and amplitude.  In line with 
previous studies [30], aged neurons showed an 
increased number of transients per minute, coupled with 
decreased Ca2+ spike amplitude, when compared with 
control cells (Fig. 4A-D).  Compared with age-matched 
sister cultures, L-CS treatment resulted in a significant 
reduction of spike frequency and increased transient 
amplitudes in both control and aged cultures (Fig. 4A-
D).  These results in combination with the altered levels 
of [Ca2+]i found in the soma of aged neurons left open 
the possibility that the changes in somatic [Ca2+]i 
transients might be due to defective intracellular cation 
handling or to increased synaptic activity.  To test these 
possibilities, we evaluated Ca2+ transients in dendrites 
as these compartments did not exhibit signs of Ca2+ 
dysregulation (Fig. 1E-F).  Dendrites of vehicle- and L-
CS-treated aged cultures did not show significant 
 
 
Figure 3.  Effects of aging and L-CS on mitochondrial functioning, morphology, and ROS generation in cortical neurons.  
(A-B) Time course of CCCP-driven dissipation of the mitochondrial Δp.  Traces represent the average response to 10 µM CCCP 
exposure.  (ControlVeh: n=189 cells and ControlL-CS n=228; AgedVeh n=255 cells and AgedL-CS n=240 cells obtained from 4-5 independent 
experiments).  Please, note that aged cortical cultures require a shorter CCCP exposure time (4 min) to reach resting fluorescence 
levels (B).  (C) Dot plots depict quantification of data shown in A and B.  Note that the maneuver, along with the normalization 
procedure (expressed as Fx/FCCCP), represents an estimation of the resting mitochondrial Δp.  (D)  Representative super-resolution 
confocal images of Mitotracker Green-loaded control and aged neuronal cultures treated either with L-CS or vehicle (for 
quantification see supplementary table 1, n=4-6 neurons per condition; scale bar 10 µm).  Please, note that no major morphological 
changes were observed among study groups.  (E) Dot plots depict normalized resting HEt fluorescence obtained from the four study 
groups (ControlVeh: n=361 cells and ControlL-CS n=332; AgedVeh n=233 cells and AgedL-CS n=301 cells obtained from 5-9 independent 
experiments).  Means were compared by two-way ANOVA followed by Tukey post-hoc test.  ** indicates p<0.01. 
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changes in spontaneous Ca2+ transients (Fig. 4 E-H), 
thereby suggesting that the altered somatic [Ca2+]i rises 
are primarily due to defective Ca2+ homeostasis. No 
significant differences were observed when comparing 
vehicle- and L-CS-treated control cultures 
(Supplementary Fig. 3). Of note, L-CS treatment was 
more effective in reducing spike frequency in control 
neurons compared to aged cells (Fig. 4C). Similar 
differences in somatic Ca2+i transients were obtained 
when replicating the experiments with the slower (but 
ratiometric) dye fura-2 (data not shown). Overall, these 
findings indicate that L-CS treatment reduces the 
altered somatic Ca2+ signaling driven by spontaneous 
synaptic activity. 
L-CS treatment reduces the age-related markers of 
neuronal demise 
 
To test whether L-CS affects the molecular markers that 
modulate neuronal functioning, western blot (WB) 
analyses were performed on cell lysates from vehicle- 
and drug-treated cultures.  When compared to control 
cultures, WB analysis of aged neurons showed 
increased expression levels of p53 and increased 
phosphorylation, and thus activation, of JNK, two 
molecules implicated in the regulation of cellular 
senescence programs (Fig. 5A-B) [31,32].  These age-
driven changes were reverted by L-CS treatment (Fig. 
5A-B).  The  drug  also  promoted  a  reduction  of pP38  
 
 
Figure 4.  Effects of aging and L-CS on Ca2+ transient frequency and amplitude.  (A) Representative brightfield (left) and 
fluorescent (middle and right) micrographs of a fluo-4-loaded agedL-CS neuronal culture employed to monitor spontaneous Ca2+ 
transients (scale bar 25 µm).  Greyscale fluorescent images show cortical neurons before (middle) and during (right) a Ca2+ transient.  
(B) Time course of somatic spontaneous Ca2+ oscillations in the four study groups.  Each trace depicts a single neuron representative 
of at least three independent experiments.  (C) Bar graphs depict average transient frequencies of vehicle- or L-CS-treated control 
and aged neurons (ControlVeh: n=499, ControlL-CS n=253, AgedVeh n=367, and AgedL-CS n=293 cells obtained from 15-38 experiments).  
(D) Bar graphs depict the average Ca2+ transient amplitude in the four study groups [samples are the same as in (C)].  (E) 
Representative greyscale fluorescent micrographs of a fluo-4-loaded primary dendrite before (left) and during (right) a Ca2+ transient.  
(F)  Time course of dendritic spontaneous Ca2+ oscillations in the AgedVeh and AgedL-CS cultured neurons.  Each trace depicts a single 
dendrite representative of at least three independent experiments.  (G) Bar graphs depict average transient frequencies of AgedVeh 
and AgedL-CS dendrites (AgedVeh n=21 and AgedL-CS n=27 dendrites from 12-18 experiments).  (H) Bar graphs depict the average 
dendritic Ca2+ transient amplitude in the four study groups [samples are the same as in (G)].  In C and D means were compared by 
two-way ANOVA followed by Tukey post-hoc test.  In G and H means were compared by unpaired Student t-test.  ** indicates p<0.01, 
n.s. indicates not significant. 
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Figure 5. Effects of aging and L-CS on senescence-related molecular markers.  Western blots show L-CS-or vehicle-driven 
effects on senescence-associated markers obtained from protein extracts of control and aged cortical cultures.  Each image is 
representative of three independent experiments.  (A)  Bar graphs depict p53 levels in the four study groups (n=3).  (B)  Bar graphs 
depict pJNK levels in the four study groups (n=3).  (C)  Bar graphs depict pP38 levels in the four study groups (n=3).  (D)  Bar graphs 
depict pAKT levels in the four study groups (n=3).  (E)  Bar graphs depict pERK5 levels in the four study groups (n=3).  Means were 
compared by two-way ANOVA followed by Tukey post-hoc test. * indicates p<0.05, ** indicates p<0.01, n.s. indicates not significant. 
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levels, a kinase associated with senescence (Fig. 5C).  
When analyzed by ANOVA, the changes showed a 
trend towards significance (Fig. 5C; Tukey post-hoc 
test, P=0.06) and reached statistical significance when 
not corrected for multiple comparisons (Fisher LSD 
post-hoc test, P=0.01).  No drug-related effects were 
observed in the control cultures (Fig. 5C).  In parallel, 
we investigated age- and drug-related effects on the 
active forms of AKT and ERK5 (pAKT and pERK5, 
respectively), two kinases involved in neuronal survival 
[33,34].  L-CS treatment was effective in reverting age-
driven down-regulation of pERK5 and pAKT (Fig. 5D-
E).  The drug also promoted increased pAKT levels in 
control cultures (Fig. 5D).  Overall, these findings 
indicate that L-CS treatment decreases the levels of 
senescence-associated markers and, at the same time, 
corrects age-driven loss of pro-survival molecules.    
 
DISCUSSION 
 
In this study, we used an in vitro model to characterize 
the effects of pharmacological blockade of de novo 
ceramide biosynthesis on neuronal senescence. The 
results indicate that exposure to the SPT inhibitor, L-
CS, concurrently lowers ceramide levels in aged 
neurons and attenuates critical molecular and functional 
changes induced by aging.  In particular, we found that 
L-CS actively counteracts the age-related mitochondrial 
dysfunction and neuronal Ca2+ dyshomeostasis.   
 
Age-related functional and molecular changes on 
cultured cortical neurons 
 
Long-term culturing of cortical neurons promoted 
significant changes in cytosolic and subcellular [Ca2+]i 
levels (Figs. 1 and 2).  These findings are in line with 
and lend further support to the “Ca2+ hypothesis of brain 
aging” [5,25,35].  This model posits that changes in the 
mechanisms that regulate [Ca2+]i homeostasis play a 
pivotal role in the expression of physiological and 
pathological aging [35].  Our findings extend this notion 
and indicate that age-driven [Ca2+]i dysregulation 
extend to and differentially affects subcellular 
compartments. 
 
A large body of evidence indicates that mitochondrial 
dysfunction is a crucial regulator of cellular senescence 
and age-related pathologies [1,36,37].  In agreement 
with this notion, our aged neurons show overt signs of 
mitochondrial Ca2+ accumulation and organelle 
dysfunction, as indicated by the presence of significant 
Δp loss when compared to control cultures (Fig. 3). 
Unexpectedly, no significant changes in mitochondrial 
morphology, a proxy of the organelle and cellular 
health, were found in the aged neurons (Fig. 3D). A 
possible explanation for this lack of effect might be 
found in work indicating that functional alterations 
often precede the appearance of morphological changes 
[38].  Mitochondria are also the primary generator of 
ROS (Supplementary Fig. 4) and compelling evidence 
indicates that the organelle dysfunction participates in 
the build-up of oxidative stress that occurs upon aging 
[1].  In line with this notion, we found that aged neurons 
show a modest (≈20%) but significant increase in ROS 
production when compared to control neurons at rest 
(Fig. 3E). 
 
No changes were observed in the amount of ER-Ca2+ 
release when comparing aging and control neurons (Fig. 
2D-E), thereby ruling out a significant contribution 
exerted by ER stress on the senescent phenotype of our 
cells.  Similarly, when comparing aged and control 
cultures, no significant changes were observed in the 
overall activity of the NCX (Fig. 2F-H).  However, age-
driven alterations in the NCX timing of activation were 
observed (Fig. 2F), a modification that may contribute 
to the [Ca2+]i alterations observed in our model [39]. 
 
Growing evidence indicates that neuronal 
hyperexcitability is a crucial early feature of aging-
related conditions, such as AD [29,40,41].  Previous 
findings from our and other laboratories have shown 
that neuronal cultures display patterns of spontaneous 
Ca2+ oscillations that mirror the neuronal firing status 
and the in vivo phenotype [29,40,41].  The analysis of 
this spontaneous synaptic activity indicates that aged 
neurons exhibit an increased frequency of [Ca2+]i 
transients along with decreased spike amplitudes, two 
indirect signs of hyperexcitability [29,41].  These 
findings parallel in vivo observations in hippocampal 
and cortical neurons of clinical and preclinical models 
of physio-pathological aging [30,42–44].  
 
Along with functional changes, aged cortical neurons 
showed alterations in molecular hallmarks associated 
with neuronal senescence [45–47].  We found that aged 
neurons exhibit higher expression levels of p53 and 
increased activation of pJNK and pP38, three molecules 
implicated in neuronal demise [48,49].  In parallel, we 
observed an age-dependent decrease in the levels of the 
pro-survival kinases pAKT and pERK5 [33,50]. 
 
Functional and molecular effects of L-CS on aged 
neurons 
 
L-CS supplementation is largely employed in in vitro 
and in vivo settings to promote a robust decrease in 
ceramide levels through the inhibition of the de novo 
biosynthetic pathway [15,19,20,51–54].  In line with 
this notion, L-CS was effective in reducing the 
ceramide pool in our aged neurons when compared to 
vehicle-treated cells.  A modest drug-related effect was 
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also observed in control cells.  This discrepancy can be 
explained by previous findings indicating that the de 
novo pathway plays a primary role in ceramide 
biosynthesis during senescence [15], a mechanism 
likely occluded in our control cultures.  Of note, a 
modest increase in ceramide levels was observed in 
aged cultures when compared to control cells.  In that 
regard, several explanations are conceivable.  One 
explanation relates to the limits of our experimental 
setting.  Neurons in cultures remain viable and healthy 
for a relatively short time, thereby compressing the 
timescale of the physio-pathological processes that 
occur in vivo.  On the other hand, one can envision that, 
in our model, ceramide build-up is, at least in part, 
counteracted by the activity of ceramide-degrading 
enzymes (likely ceramidase) which in turn contribute to 
the increase in ceramide by-products (i.e.: sphingosine), 
a likely hypothesis suggested by our lipidomic analysis 
(see Supplementary Fig. 2). 
 
Ceramide accumulation, following acute stressful 
challenges, participates in the activation of apoptosis in 
several cellular systems, including neurons.  Given the 
central role of mitochondria in the activation of 
apoptotic signals, it is therefore conceivable that the L-
CS-driven reduction in ceramide levels may also affect 
the organelle functioning.  In line with this notion, we 
found a robust recovery (≈50%) of the mitochondrial 
Δp and a reduction of the ROS production in L-CS-
treated neurons when compared to vehicle-treated aged-
matched cultures.  These findings are also in line with 
previous reports showing that ceramides contribute to 
mitochondrial dysfunction by impairing the organelle 
electron transport chain, generating ROS, and 
promoting the permeabilization of the mitochondrial 
outer membrane [55,56].  ROS also contribute to the 
activation of ceramide-releasing enzymes [57], thereby 
suggesting the presence of a feed-forward loop in which 
ceramide accumulation, mitochondria impairment, and 
oxidative stress act synergistically to promote neuronal 
impairment. 
 
To investigate the downstream effectors of the 
mitochondrial pathways involved in neuronal 
dysfunction, we evaluated changes in levels of p53, 
pJNK, and pP38.  The selection of these proteins was 
driven by the fact that 1) these factors are altered in and 
participate to senescence-related processes; 2) their 
activity is intertwined with mitochondrial dysfunction; 
3) their levels are modulated by ceramides [15,48,58–
60].  L-CS was found to be effective in reducing the 
increased levels of p53, pJNK, and pP38 (Fig. 5) shown 
by the aging cultures.  These results support the idea 
that L-CS, by reducing de novo ceramide biosynthesis, 
prevents the mitochondria-driven activation of 
senescent-related pathways. 
Our findings converge towards the possibility of a 
beneficial effect of L-CS in aging cultures.  The 
analysis of the data on spontaneous synaptic activity 
supports this hypothesis and indicates that L-CS is 
effective in reducing the aberrant neuronal firing of 
aged cultures (Fig. 4).  Thus, one can envision that the 
age-dependent accumulation of ceramide adducts is a 
critical contributor to the functional alterations in 
neuronal connectivity observed in either preclinical 
models or neurological conditions [44,61,62].  A robust 
drug-related effect was also observed in control 
cultures, a setting that exhibited only modest reductions 
of ceramide levels (Fig. 5).  This discrepancy can be, at 
least in part, explained by drug-related effects on the in 
vitro neuronal development [7] and/or by off-target 
effects of the compound [63]. 
 
CONCLUSIONS 
 
The results presented here provide experimental support 
for the presence of an aging-related cascade of events 
that include mitochondrial dysfunction, Ca2+ 
dysregulation, impaired neuronal Ca2+ signaling, and 
alterations of aging-related markers in which de novo 
ceramide biosynthesis acts a critical intermediate.  Our 
findings indicate that ceramide modulation is not a mere 
response to aging-related stimuli but may play instead 
an active role in shaping the senescence-related 
processes [13].  Indeed, they are in line with a growing 
body of literature supporting a key role for lipids and 
lipid dysmetabolism in aging and neurodegenerative 
conditions [12,13,64–69].  In this context, ceramides are 
emerging as important peripheral biomarkers of age-
related pathologies since changes in their plasmatic 
levels are now considered to be highly predictive of 
aging-related cognitive decline and conversion to AD 
[13,70,71]. 
 
The present study has several limitations.  For instance, 
our near-pure neuronal system does not investigate the 
impact of ceramides on the senescent phenotype of non-
neuronal cells (i.e., astrocytes, microglia, etc.), an 
important area of investigation given the key role 
played by ceramides in promoting the glia-mediated 
release of pro-inflammatory cytokines in the context of 
cell death [16,52,72]. Furthermore, due to the 
limitations of our experimental setting, we have not 
explored sex-related differences as gender has been 
recently shown to have a significant impact on ceramide 
metabolism [66]. Our study focused on the 
pharmacological manipulation of the SPT, as the 
enzyme is the rate limiting factor in the de novo 
biosynthetic pathway. The potential contribution of 
ceramide synthase (CeS), which acts downstream of 
SPT, in the age-related buildup of ceramides warrants 
further investigation.  Finally, the L-CS-driven effects 
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occasionally observed in control cultures suggest that 
the compound may also act through mechanisms 
independent on ceramide biosynthesis, which warrant 
further investigation.  Although the L-CS biological 
activity is distinct from the one modulated by D-
cycloserine (an N-methyl-D-aspartate receptor co-
agonist), it cannot be ruled out that a marginal 
isomerization of the compound accounts for some of the 
observed off-target effects.   
 
Our results raise several intriguing questions on the 
interplay between ceramides and other 
neurodegenerative markers.  For instance, do ceramides 
act on the same targets affected by proteins and 
pathways involved in AD, PD, or ALS (i.e., amyloid, 
tau, α-synuclein, TDP-43) or do they engage 
independent and/or synergistic pathways?  Is there a 
common molecular trigger for the accumulation of 
ceramides and misfolded proteins? Does the 
manipulation of the pathological accumulation of 
amyloid, tau, α-synuclein, or TDP-43 affect ceramide 
metabolism or vice versa?  Testing these questions in 
disease-relevant preclinical and clinical settings will 
have a great translational value.  Although descriptive, 
the present results indicate that the pharmacological 
modulation of the de novo ceramide biosynthesis may 
be a promising target for the treatment of age-related 
pathologies as shown in preclinical models of AD [20], 
insulin resistance [51], and microglia-driven 
inflammation [52], conditions in which the ceramide 
build-up has been proposed to be involved in the 
disease onset and progression.  Also, the L-CS off-
target effects and its short half-life offer the possibility 
to investigate and test novel, brain penetrant, long-
lasting, and more selective SPT inhibitors [16]. 
 
MATERIALS AND METHODS 
 
Materials 
 
Culture media and sera were purchased from GIBCO 
(ThermoFisher). All the fluorescent indicators 
employed in the study (fura-2 AM, fluo-4 AM, 
hydroethidine, TMRE, and MitotrackerGreen FM) were 
obtained from Molecular Probes (ThermoFisher).  
Unless otherwise specified, all commonly used 
chemicals were from Sigma-Aldrich. 
 
Neuronal cortical cultures 
 
The procedures involving animals were approved by the 
institutional Ethics Committee (47/2011/CEISA/COM) 
and performed following institutional guidelines and 
national and international laws and policies. Female 
mice were caged in groups, while male mice were 
single-housed.  Mice were kept on a 12:12 light/dark 
cycle and had free access to food and water.  All efforts 
were made to minimize the number of animals 
employed and their suffering. 
 
Neuronal cortical cultures were, as previously described 
[41], prepared from fetal CD1 mice at 14 days of 
gestation and plated onto Poly-DL-lysine (100 µg/ml) 
and laminin (5 µg/ml) coated Petri dishes or glass 
coverslips.  Three days after plating, the proliferation of 
non-neuronal cells was halted by the addition of 
cytosine β-D-arabinofuranoside (5 µM).  Every three 
days 25% of the growth medium was replaced with 
fresh Neurobasal.  Routinely-performed functional 
experiments and visual inspections show that the 
cytostatic treatment robustly affected glia proliferation 
(around 5–10 % of non-neuronal cells per culture). 
 
Ceramide quantification 
 
Ceramides analysis was performed as previously 
described [73].  Briefly, 100 µL of sample,  lysed with a 
probe sonicator, were mixed to 300 µL of 
chloroform:methanol 2:1 v/v with an internal standard 
mix containing sphinganine d17:0, sphingosine d17:1, 
sphingosine-1-phosphate d17:1, sphinganine-1-
phosphate d17:0, sphingosine-1-phosphate d17:1, 
glucosylceramide (d18:1/17:0), and ceramide 
(d18:1/17:0).  The organic phase was dried and 
reconstituted in 100 µL of H2O : methanol : isopropanol 
: acetonitrile (7:2:0.5:0.5, v/v).  The LC-MS/MS system 
was an HPLC Alliance HT 2795 Separations Module 
coupled to Quattro UltimaPt ESI tandem quadrupole 
mass spectrometer (Waters Corporation) operating in 
the positive ion mode.  For the chromatographic 
separation, Ascentis Express Fused-Core C18 2.7 µm, 
7.5 cm x 2.1 mm columns were used.  Elution was 
achieved through a gradient of mobile phases, starting 
from 50% to 100% of methanol:isopropanol:acetonitrile 
4:1:1 v/v (solvent B), water was used as solvent A.  The 
total run time was 25 min.  The flow rate was 0.25 
mL/min.  The capillary voltage was 3.8 kV, source 
temperature was 120 °C, the de-solvation temperature 
was 400 °C, and the collision cell gas pressure was 
3.62×10−3 mbar argon.  Chromatograms were used 
quantify the following molecules: sphinganine (d18:0), 
sphingosine (d18:1), sphinganine-1-phosphate (d18:0), 
sphingosine-1-phosphate (d18:1), C16 ceramide 
(d18:1/16:0), C16 dihydroceramide (d18:0/16:0), C18 
Ceramide (d18:1/18:0), C16 glucosyl(ß) ceramide 
(d18:1/16:0), C22 ceramide (d18:1/22:0), C24 ceramide 
(d18:1/24:0) and C24 dihydroceramide (d18:0/24:0). 
 
Ceramide levels are expressed as relative abundance.  
The absolute quantification of each species was 
performed by normalizing the peak area of each 
ceramide with its own internal standard (i.e. Cer C16 vs 
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Cer C17).  To reduce the variability related to our 
experimental model (as inter-culture heterogeneity was 
observed), a further normalization was carried out 
within the same culture, thereby obtaining a relative 
quantification that allows more reliable comparisons 
among the three biological replicates. 
 
Live-cell imaging 
 
Live neuronal imaging experiments were performed, as 
previously described [74,75], by employing a Nikon 
Eclipse TE300 inverted microscope equipped with a 
Xenon lamp, a 40× Nikon epifluorescence oil 
immersion objective (N.A.: 1.3) and a 12-bit Orca CCD 
camera (Hamamatsu).  Alternatively, experiments were 
performed with a Zeiss Axio Examiner.D1 upright 
microscope equipped with an Optoscan monochromator 
(Cairn), a 20x or 40x Zeiss epifluorescence water 
immersion objective (N.A.: 1.0), and a 16-bit Evolve 
512 EMCCD camera (Photometrics).  Images were 
acquired and stored for offline analysis with Metafluor 
7.7 software (Molecular Devices). 
 
[Ca2+]i  measurements 
 
Measurements of [Ca2+]i were performed by employing 
the ratiometric dye fura-2 or the single wavelength dye 
fluo-4, as previously described [74,75].  Briefly, cortical 
cultures were loaded with fluo-4 AM (3 μM) or fura-2 
AM (3 μM) plus 0.1% Pluronic F-127 (ThermoFisher) 
in a HEPES-buffered saline solution (HCSS) whose 
composition was: 120 mM NaCl, 5.4 mM KCl, 0.8 mM 
MgCl2, 20 mM HEPES, 15 mM glucose, 1.8 mM 
CaCl2, 10 mM NaOH, and pH 7.4.  After 30 min of 
incubation with the selected dye, cells were washed and 
incubated in the dark for a further 30 min in HCSS. 
 
Resting [Ca2+]i levels were recorded as fura-2 ratios and 
expressed as % changes compared to vehicle-treated 
adult cultured neurons.  No changes in the time of 
exposure, gain, electron multiplier settings, filter set, or 
lamp power occurred during resting [Ca2+]i 
measurements.  Pharmacological manipulations were 
performed by applying drugs at the indicated time 
points and washed out by employing an automated 
perfusion system (Biologic).  During all the fura-2 
[Ca2+]i measurements HCSS was supplemented with 
200 - 500 nM TPEN (Merck) to avoid interferences due 
to other metal ions (i.e. zinc) with [Ca2 +]i-dependent 
fluorescence signals [76,77]. 
 
Spontaneous [Ca2+]i spikes analysis 
 
Fluo-4 AM (Ex λ: 473 ± 20 nm, Em λ: 525 ± 25 nm) 
was employed to measure spontaneous [Ca2 +]i 
transients.  Images were acquired at full-frame 
resolution (512 x 512 pixels; binning 1x) at 1 Hz 
sampling rate for up to 5 min.  Conversely, to evaluate 
dendritic Ca2+ transients, the camera frame was cropped 
(with a 1x binning) around proximal primary dendritic 
branches and images acquired at a 10 Hz sampling rate 
for up to 60 s. 
 
Fluorescence changes of each cell/dendrite were 
expressed as a percentage of baseline fluorescence (% 
of basal fluorescence).  Spontaneous [Ca2+]i transients 
from vehicle- and L-CS-treated cultures were analyzed 
with a custom made MATLAB code, as previously 
described [29,41].  For statistical analysis, we took into 
consideration only fluorescence values 50 % larger than 
baseline for somata and 25 % larger than baseline for 
dendrites.  Cells that failed to display Ca2+ transients 
when the threshold was set at 25% of the baseline were 
excluded from the analysis. 
 
Measurements of mitochondrial Δp 
 
Measurements of the mitochondrial Δp were performed 
as previously described [74], with minor modifications.  
Briefly, cultured cortical neurons were loaded with 
50 nM of TMRE for 30 min in culture medium at 37° C.  
TMRE fluorescence (Ex λ: 530 ± 15 nm, Em λ: 575–
610 nm) changes of each cell (Fx) were normalized to 
basal fluorescence intensity (FCCCP) obtained by 
exposing the cells to the mitochondrial uncoupler CCCP 
(10 µM).  Experiments were halted when, after CCCP 
application, the fluorescence signal was stable for up to 
30 s. 
  
Mitochondria morphology analysis 
 
Neurons plated on glass coverslips were washed and 
loaded for 30 min at room temperature with 
MitoTracker Green FM (100 nM in HCSS), a 
mitochondrially-targeted and Δp-insensitive dye.  Cells 
were imaged on the stage of an inverted Zeiss LSM800 
Super-resolution confocal microscope equipped with a 
488 nm LED-based laser line, a 63x oil immersion 
objective (N.A.: 1.4), and an Airyscan imaging module.  
Appropriate emission filter-sets were selected with the 
built-in Smart Setup function.  Laser power was 
maintained at the minimum (0.65%) to achieve an 
optimum signal-to-noise ratio and avoid 
photobleaching.  Acquisition parameters (i.e., detector 
and digital gain) were constant among experimental 
sessions.  Single-plane images were acquired with the 
Zeiss ZEN proprietary software and stored for offline 
analysis. 
 
Confocal micrographs were Airyscanned to obtain 
super-resolution images that were further analyzed with 
the ImageJ-based MiNA toolkit, following the 
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developer workflow [27].  Briefly, images were 
preprocessed (applied algorithms: Unsharp Mask, 
CLAHE, Median Filtered), then binary transformed and 
skeletonized to allow parameters generation and 
recording. 
 
ROS measurements 
 
Evaluation of basal ROS production was performed by 
employing hydroethidine (HEt; Ex λ: 530 ± 15 nm, Em 
λ: 575–610 nm), a fluorescent probe sensitive to ROS.  
Basal ROS production levels were measured after 
loading vehicle- or L-CS-treated cultures with HEt (5 
µM).  Cells were loaded for 2 h at 37 °C to allow dye 
oxidation by endogenously released ROS.  Resting 
fluorescence signals were recorded and normalized to 
that of vehicle-treated control cultured neurons. 
 
Western blot analysis 
 
Western blot analysis was performed as previously 
described [50,78].  Briefly, control and treated cells 
were lysed in ice-cold RIPA buffer (phosphate buffer 
saline pH 7.4 containing 0.5% sodium deoxycholate, 
1% Igepal, 0.1% SDS, 5mM EDTA, 1% protease and 
phosphatase inhibitor cocktails).  Protein lysates (20 μg) 
were separated on 8–14% SDS–polyacrylamide gel and 
electroblotted onto a polyvinyldifluoride membrane 
(PVDF). Nonspecific binding sites were blocked by 5% 
non-fat dry milk (Bio-Rad Laboratories) in Tris 
buffered saline (TBS: 20mMTris– HCl, pH 7,4, 
containing 150mM NaCl) for 30 min at RT.  
Membranes were then incubated overnight at 4°C with 
the following primary antibodies, diluted with TBS 
containing 0,1% Tween 20 (TBS-T) and 5% non-fat dry 
milk: rabbit HRP-conjugated actin 1:10000 (Cell 
Signaling); rabbit p-JNK and JNK 1:200 (Santa Cruz); 
p-ERK1,2 1:200 (Santa Cruz); rabbit p-Akt 1:1000 
(Cell Signaling); Erk1,2 1:200 (Santa Cruz); rabbit p-
P38 and rabbit P38 1:1000 (Cell Signaling); rabbit P53 
1:1000 (Cell Signaling); rabbit p-ERK5 and rabbit 
ERK5 1:1000 (Cell Signaling).  As secondary 
antibodies, peroxidase conjugated anti-rabbit or anti 
mouse IgG (1:10000; Vector Laboratories) were used.  
Immunoreactive bands were visualized by ECL (Bio-
Rad Laboratories), according to the manufacturer’s 
instructions.  The relative densities of the 
immunoreactive bands were determined and normalized 
with respect to Actin, using ImageJ software.  Values 
were given as relative units (RU). 
 
RNA extraction and qRT-PCR 
 
RNA extraction and qRT-PCR were performed as 
previously described [78].  Briefly, total RNA 
extraction was performed with the NucleoSpin RNA 
isolation kit (Macherey-Nagel).  One µg of RNA was 
retro-transcribed by employing the High Capacity 
RNA-to-cDNA Kit (ThermoFisher Scientific).  qRT-
PCR was performed on an Abi 7900HT Sequencing 
Detection System (ThermoFisher Scientific).  Sptlc-2 
relative expression was corrected for GAPDH here 
employed as endogenous control.  Samples were run in 
triplicate.  Sptlc-2 relative fold change was calculated 
with the ΔΔCt method. 
 
Data and statistical analysis 
 
Data are represented as box plots.  Center lines and 
boxes represent medians and means, respectively.  Box 
limits indicate 25th and 75th percentiles, and whiskers 
extend 1.5 times the interquartile range from the 25th 
and 75th percentiles [79].  No statistical methods were 
used to predetermine the sample size.  Statistical 
analysis was performed by two-way ANOVA (cell 
culture age vs. treatment) followed by Tukey’s post-hoc 
test.  Differences in ceramide levels and dendritic Ca2+ 
transients were analyzed by unpaired Student’s t-test.  
Experimenters were not blinded to treatment allocation.  
By conventional criteria, P values are represented as * 
for P ≤ 0.05 and ** for P ≤ 0.01. 
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SUPPLEMENTARY MATERIAL 
 
 
 
Supplementary Figures 
  
 
 
Supplementary Figure 1.  Effects of aging and L-CS on de novo ceramide biosynthesis.  (A) The pictogram illustrates a 
simplified version of the steps involved in the three ceramide biosynthetic pathways.  Please, note that L-CS acts by inhibiting SPT in 
the de novo pathway.  (B) Bar graphs depict the relative abundance of sphinganine in vehicle- and L-CS-treated aged neurons (n=3).  
(C) Bar graphs depict the relative abundance of sphingosine in vehicle- and L-CS-treated aged neurons (n=3).  (D) Bar graphs depict 
the relative abundance of ceramides in vehicle- and L-CS-treated control neurons (n=3).  (E) Bar graphs depict the relative abundance 
of ceramides in vehicle-treated control and aged neurons (n=3).  Means were compared by unpaired Student t-test.  ** indicates 
p<0.01. 
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Supplementary Figure 2.  Effects of aging and L-CS on de novo ceramide biosynthesis.  (A) Bar graphs depict the relative 
abundance of the molecules as measured by LC-MS/MS in vehicle- and L-CS-treated control neurons (n=3).  (B) Bar graphs depict the 
relative abundance of the molecules as measured by LC-MS/MS in vehicle- and L-CS-treated aged neurons (n=3).  (C) Bar graphs 
depict the relative abundance of the molecules as measured by LC-MS/MS in vehicle-treated control and aged neurons (n=3).  (D) Bar 
graphs depict mRNA levels of Sptlc-2 measured by real-time PCR in control and aged cultures (n=3-5 per condition).  Means were 
compared by unpaired Student t-test.  * indicates p<0.05, ** indicates p<0.01. 
 
 
www.aging-us.com 6356 AGING 
 
  
 
 
Supplementary Figure 3.  Effects of L-CS on dendritic Ca2+ transient in control cultures.  (A) Bar graphs depict average 
transient frequencies of ControlVeh and ControlL-CS dendrites (ControlVeh n=11 and ControlL-CS n=14 dendrites from 6-7 experiments).  
(B) Bar graphs depict the average dendritic Ca2+ transient amplitude in the two study groups [samples are the same as in (B)].  Means 
were compared by unpaired Student t-test. 
 
 
Supplementary Figure 4.  Mitochondria are the primary source of ROS in our cortical cultures.  To evaluate the primary 
source of ROS in our system we performed pharmacological manipulations aimed at selectively observing ROS of mitochondrial and 
non-mitochondrial origin.  HEt-loaded control cortical neurons were challenged with NMDA + glycine (50 µM + 10 µM), a maneuver 
that triggers a robust generation of ROS from both mitochondrial and non-mitochondrial sources [80,81].  After 5 minutes, NMDA 
receptor (NMDAR) overactivation was halted by bath application of the non-competitive NMDAR antagonist MK-801 (10 µM).  In (A), 
traces depict NMDA-driven ROS generation in control neurons (black trace) and in cells bathed and challenged in a solution in which 
glucose was replaced with pyruvate (15 mM), an established paradigm aimed at promoting ROS generation only from mitochondria.  
No differences were observed between the two conditions.  In (B), neurons were challenged with (blue trace) or without (black trace) 
apocynin (500 µM), an inhibitor of NADPH oxidase activity.  Means were compared by unpaired Student t-test.  No differences were 
observed between the two conditions.  Collectively, these findings indicate that mitochondria are the primary source of ROS in our 
cortical cultures. 
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Supplementary Table 
 
Supplementary Table 1.  Data related to mitochondrial morphology analysis as shown in Fig. 3. 
 ControlVeh ControlL-CS AgedVeh AgedL-CS P 
Individuals (n) 191.00 ± 46.27 168.4 ± 34.11 251.00 ± 33.49 217.80 ± 54.14 >0.05 
Networks (n) 64.25 ± 16.28 38.6 ± 11.69 78.16 ± 9.81 71.2 ± 15.61 >0.05 
Mean Branch Length (µm) 0.602 ± 0.020 0.579 ± 0.012 0.560 ± 0.016 0.547 ± 0.010 >0.05 
Median Branch Length (µm) 0.456 ± 0.014 0.467 ± 0.013 0.435 ± 0.014 0.417 ± 0.007 >0.05 
Length Standard Deviation 
(µm) 
0.531 ± 0.035 0.464 ± 0.015 0.486 ± 0.017 0.490 ± 0.008 >0.05 
Median Network Size (n of 
branches) 
4.25 ± 0.47 4.40 ± 0.40 4.41 ± 0.55 4.10 ± 0.45 >0.05 
Mitochondrial Footprint 
(µm2) 
139.19 ± 30.06 241.26 ± 47.43   189.39 ± 27.35 153.51 ± 24.35 >0.05 
 
 
